title: Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy.
abstract: The aim of this study was to examine the effect of intranasal administration of salmon calcitonin to a group of 24 postmenopausal women with severe, established osteoporosis (t score < -2.5 SD) and more than one vertebral fracture. The patients were treated with 200 IU of nasal salmon calcitonin daily for 2 months with a subsequent pause of 2 months (3 cycles) and 500 mg calcium daily over a total of 12 months in an open randomized study. The patients were compared with an age matched control group of 18 women of a similar clinical status who were treated with calcium and vitamin D only. In the nasal calcitonin treatment group an increase in the trabecular axial bone density of 2.8% was achieved, as well as increase in trabecular appendicular (forearm) bone density of 1.6%, together with a cortical bone density increase of 1.8% axial and 1% appendicular. Initially, elevated values of urinary deoxypyridinoline were found in 12 women in the nasal calcitonin treatment group; these levels returned to normal under salmon calcitonin nasal therapy and documented the inhibition of increased osteoclastic activity. Cyclic intermittent calcitonin nasal therapy led to a general increase in trabecular and cortical axial and appendicular bone density, marked alleviation of the subjective sensation of pain, and a reduction in the daily dose of accompanying nonsteroidal anti-inflammatory drugs by 50%.
authors.affiliation: Second Department of Internal Medicine with Rheumatology and Osteology, Kaiser Franz Joseph Hospital, Vienna, Austria.
authors.forename: P
authors.initials: P
authors.lastname: Peichl
authors.forename: B
authors.initials: B
authors.lastname: Rintelen
authors.forename: W
authors.initials: W
authors.lastname: Kumpan
authors.forename: H
authors.initials: H
authors.lastname: Bröll
mesh_terms: D000281:Administration, Intranasal; D000596:Amino Acids / Q000652:urine; D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001132:Arm / Q000000981:diagnostic imaging; D015415:Biomarkers / Q000652:urine; D015519:Bone Density / Q000187:drug effects*; D001862:Bone Resorption / Q000517:prevention & control; D002116:Calcitonin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002118:Calcium / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D010147:Pain Measurement / Q000523:psychology; D010865:Pilot Projects; D012474:Salmon; D016103:Spinal Fractures / Q000517:prevention & control; D013131:Spine / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D000596:Amino Acids; D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D015415:Biomarkers; D014807:Vitamin D; C015484:pyridinoline; C028815:salmon calcitonin; C036020:deoxypyridinoline; D002116:Calcitonin; D002118:Calcium